Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Find therapies in clinical trials near you – page 6

recruiting
3 987
countries
28
conditions
2 109

726 trials match your criteria

Alcoholism

Recruiting

Study on Sodium Oxybate for Reducing Alcohol Consumption in Patients with Alcohol Addiction

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Oxybate

Smoking cessation therapy+1

Recruiting

Study on Cytisine for Quitting Nicotine E-Cigarettes and Tobacco in Motivated Individuals

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Cytisine

Sjogren's syndrome

Recruiting

Study on the Effectiveness and Safety of Deucravacitinib for Adults with Active Sjogren's Syndrome

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Deucravacitinib

Neoplasm malignant

Recruiting

Study on the Long-term Safety and Efficacy of Pembrolizumab and Lenvatinib for Patients with Advanced Tumors

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Favezelimab

Amyotrophic lateral sclerosis

Recruiting

Study on the Safety and Effectiveness of Dazucorilant for Patients with Amyotrophic Lateral Sclerosis (ALS)

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Dazucorilant

Sjogren's syndrome

Recruiting

Phase III trial evaluating ianalumab with background drug combination in patients with Sjögren's disease

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Emtricitabine

Plasma cell myeloma

Recruiting

Ramantamig (JNJ-79635322) with drug combination versus standard therapy in newly diagnosed multiple myeloma patients not eligible for stem cell transplant

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib

Idiopathic pulmonary fibrosis

Recruiting

Efficacy and Safety of Oral PIPE-791 in Adults with Idiopathic Pulmonary Fibrosis: A Phase 2 Randomized, Double‑Blind, Placebo‑Controlled Study

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years

Dermatitis atopic

Recruiting

Study of Camoteskimab and Sodium Chloride Placebo in Adults with Moderate-to-Severe Atopic Dermatitis

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride

Adenocarcinoma pancreas

Recruiting

First‑line Study of RMC‑9805 with Investigator’s Choice Chemotherapy Drug Combination vs Chemotherapy Alone in Patients with Metastatic KRAS G12D‑Mutated Pancreatic Adenocarcinoma

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:(2S)-2-CYCLOPENTYL-2-[(5S)-2-[(2R,3R)-3-CYCLOPROPYL-1-METHYLAZIRIDINE-2-CARBONYL]-2,7-DIAZASPIRO[4.4]NONAN-7-YL]-N-[(6S,8S,14S)-21-[5-(4-CYCLOPROPYLPIPERAZIN-1-YL)-2-[(1S)-1-METHOXYETHYL]PYRIDIN-3-YL]-18,18-DIMETHYL-9,15-DIOXO-22-(2,2,2-TRIFLUOROETHYL)-5,16-DIOXA-2,10,22,28-TETRAZAPENTACYCLO[18.5.2.12,6.110,14.023,27]NONACOSA-1(26),20,23(27),24-TETRAEN-8-YL]ACETAMIDE

Gastrointestinal stromal tumour

Recruiting

Phase 3 Study of GSK6042981 versus Imatinib in Adults with Previously Untreated Metastatic or Unresectable Gastrointestinal Stromal Tumors (GIST)

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Imatinib Mesilate

Neovascular age-related macular degeneration

Recruiting

Efficacy and safety of ABP 938 compared with aflibercept in participants with neovascular age‑related macular degeneration

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.